MARKET

XRTX

XRTX

Xortx Therapeutics Inc
NASDAQ
0.4110
-0.0085
-2.03%
Opening 09:30 02/11 EST
OPEN
0.4110
PREV CLOSE
0.4195
HIGH
0.4110
LOW
0.4110
VOLUME
14.87K
TURNOVER
--
52 WEEK HIGH
1.410
52 WEEK LOW
0.3820
MARKET CAP
2.86M
P/E (TTM)
-0.8693
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XRTX last week (0202-0206)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 5d ago
XORTX Extends Deadline for Vectus Renal Anti-Fibrotic Program Acquisition and Sets March Shareholder Meeting
TipRanks · 6d ago
Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Benzinga · 6d ago
XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars
NASDAQ · 6d ago
XORTX verlängert Frist für Übernahme des Renal Anti-Fibrotic Therapeutic Program von Vectus bis 31. März 2026
Reuters · 6d ago
XORTX Extends Deadline to Complete Acquisition of Vectus Renal Anti-Fibrotic Program
Reuters · 6d ago
XORTX THERAPEUTICS INC - ACQUISITION CLOSING EXTENDED TO MARCH 31, 2026
Reuters · 6d ago
More
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Webull offers XORTX Therapeutics Inc stock information, including NASDAQ: XRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XRTX stock methods without spending real money on the virtual paper trading platform.